Michael Rainone
Hematology & Oncology · Boston, MANPI 1831620582
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,300 of the $1,505 with a category attached, or 86.4%. It is spread thinly across 10 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $842 and has fallen 98.1% since, to $16 in 2024. That places this record below the midpoint for hematology & oncology clinicians in MA, where the typical reported total is $856.
Across 18 payments — averaging $83.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$324
- AstraZeneca$275
- Lilly USA, LLC$256
- Jazz Pharmaceuticals Inc.$234
- Incyte Corporation$152
- Sobi, Inc$122
- plus $141 from 4 others
What the payments were for
- Travel & lodging$60%
- Food & beverage$1,30086%
- Education$19913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 3 | $324 |
| AstraZeneca(2 entities) | 3 | $275 |
| Lilly USA, LLC | 3 | $256 |
| Jazz Pharmaceuticals Inc. | 2 | $234 |
| Incyte Corporation | 2 | $152 |
| Sobi, Inc | 1 | $122 |
| Coherus Oncology, Inc. | 1 | $74 |
| Exelixis Inc. | 1 | $27 |
| Merck | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,505 in reported general payments places this provider in the 50th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 20 | $707 |
| Ondansetron Hcl | 31 | $493 |
| Duloxetine Hcl | 18 | $296 |
| Dexamethasone | 16 | $224 |
| Oxycodone Hcl | 15 | $202 |
| Potassium Chloride | 13 | $119 |
| Prednisone | 26 | $79 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $60 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $39 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Boston
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Rupal BhattBoston$380K
- Matthew Vander HeidenBoston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.